In summary, this study implies that HMGB1 released by tumor cells and vascular endothelial cells may modulate the infiltration, polarization and function of TAMs and CD33-positive myeloid cells, thereby contributing to the progression of fibroblastic sarcomas. The gene discussed is CD33; the disease is neoplasm.